Nosis Bio is a biotechnology company based in Berkeley, California, specializing in drug delivery systems. The company focuses on developing a platform for cell-specific delivery of RNA therapeutics, leveraging deep learning and novel technologies to enhance treatment efficacy for patients. Nosis Bio is well-funded and has emerged from stealth mode, gaining recognition such as the 2022 Cystic Fibrosis Foundation Golden Ticket award. Co-founded by Jim Martineau and Chad Miller, the company aims to collaborate with pharmaceutical and biotech firms to revolutionize targeted drug delivery.